-$1.01 EPS Expected for Zogenix, Inc. (ZGNX) This Quarter
Wall Street brokerages expect Zogenix, Inc. (NASDAQ:ZGNX) to post earnings per share of ($1.01) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Zogenix’s earnings, with estimates ranging from ($1.22) to ($0.80). Zogenix reported earnings of ($0.73) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 38.4%. The company is scheduled to announce its next quarterly earnings report after the market closes on Tuesday, March 6th.
According to Zacks, analysts expect that Zogenix will report full-year earnings of ($4.45) per share for the current fiscal year, with EPS estimates ranging from ($4.69) to ($4.17). For the next year, analysts forecast that the business will report earnings of ($3.61) per share, with EPS estimates ranging from ($3.91) to ($3.09). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Zogenix.
A number of equities analysts recently commented on the company. Leerink Swann lifted their price target on Zogenix from $50.00 to $54.00 and gave the stock an “outperform” rating in a research note on Friday, February 23rd. BidaskClub upgraded Zogenix from a “hold” rating to a “buy” rating in a research note on Friday, December 29th. JMP Securities started coverage on Zogenix in a research report on Monday, November 27th. They set an “outperform” rating and a $56.00 price objective for the company. ValuEngine upgraded Zogenix from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Zacks Investment Research upgraded Zogenix from a “sell” rating to a “hold” rating in a research report on Saturday, January 27th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $43.33.
Institutional investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC purchased a new position in shares of Zogenix during the 3rd quarter valued at $226,000. Sterling Capital Management LLC purchased a new position in shares of Zogenix during the 3rd quarter valued at $237,000. Teacher Retirement System of Texas purchased a new position in shares of Zogenix during the 4th quarter valued at $409,000. Raymond James & Associates purchased a new position in shares of Zogenix during the 4th quarter valued at $460,000. Finally, Stifel Financial Corp purchased a new position in shares of Zogenix during the 2nd quarter valued at $175,000.
Shares of Zogenix (NASDAQ ZGNX) traded up $0.60 during midday trading on Wednesday, hitting $43.90. The stock had a trading volume of 459,846 shares, compared to its average volume of 629,580. The stock has a market capitalization of $1,483.13, a price-to-earnings ratio of -9.93 and a beta of 1.57. Zogenix has a twelve month low of $8.50 and a twelve month high of $44.70. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.71 and a current ratio of 2.71.
ILLEGAL ACTIVITY WARNING: “-$1.01 EPS Expected for Zogenix, Inc. (ZGNX) This Quarter” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.watchlistnews.com/1-01-eps-expected-for-zogenix-inc-zgnx-this-quarter/1910061.html.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.